JP2017222705A5 - - Google Patents

Download PDF

Info

Publication number
JP2017222705A5
JP2017222705A5 JP2017149548A JP2017149548A JP2017222705A5 JP 2017222705 A5 JP2017222705 A5 JP 2017222705A5 JP 2017149548 A JP2017149548 A JP 2017149548A JP 2017149548 A JP2017149548 A JP 2017149548A JP 2017222705 A5 JP2017222705 A5 JP 2017222705A5
Authority
JP
Japan
Prior art keywords
dosage form
oral dosage
solid oral
dimethyl fumarate
form according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017149548A
Other languages
English (en)
Japanese (ja)
Other versions
JP6430598B2 (ja
JP2017222705A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017222705A publication Critical patent/JP2017222705A/ja
Publication of JP2017222705A5 publication Critical patent/JP2017222705A5/ja
Application granted granted Critical
Publication of JP6430598B2 publication Critical patent/JP6430598B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017149548A 2012-02-07 2017-08-02 フマル酸ジメチルを含有する医薬組成物 Expired - Fee Related JP6430598B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261596202P 2012-02-07 2012-02-07
US61/596,202 2012-02-07
US201261625621P 2012-04-17 2012-04-17
US61/625,621 2012-04-17
US201261723048P 2012-11-06 2012-11-06
US61/723,048 2012-11-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014555852A Division JP6189333B2 (ja) 2012-02-07 2013-02-06 フマル酸ジメチルを含有する医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018204599A Division JP2019059732A (ja) 2012-02-07 2018-10-31 フマル酸ジメチルを含有する医薬組成物

Publications (3)

Publication Number Publication Date
JP2017222705A JP2017222705A (ja) 2017-12-21
JP2017222705A5 true JP2017222705A5 (https=) 2018-03-22
JP6430598B2 JP6430598B2 (ja) 2018-11-28

Family

ID=48947963

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014555852A Expired - Fee Related JP6189333B2 (ja) 2012-02-07 2013-02-06 フマル酸ジメチルを含有する医薬組成物
JP2017149548A Expired - Fee Related JP6430598B2 (ja) 2012-02-07 2017-08-02 フマル酸ジメチルを含有する医薬組成物
JP2018204599A Pending JP2019059732A (ja) 2012-02-07 2018-10-31 フマル酸ジメチルを含有する医薬組成物
JP2021184462A Pending JP2022024048A (ja) 2012-02-07 2021-11-12 フマル酸ジメチルを含有する医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014555852A Expired - Fee Related JP6189333B2 (ja) 2012-02-07 2013-02-06 フマル酸ジメチルを含有する医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018204599A Pending JP2019059732A (ja) 2012-02-07 2018-10-31 フマル酸ジメチルを含有する医薬組成物
JP2021184462A Pending JP2022024048A (ja) 2012-02-07 2021-11-12 フマル酸ジメチルを含有する医薬組成物

Country Status (24)

Country Link
US (7) US20130216615A1 (https=)
EP (1) EP2811994A4 (https=)
JP (4) JP6189333B2 (https=)
KR (1) KR102105217B1 (https=)
CN (5) CN113244185A (https=)
AR (1) AR089931A1 (https=)
AU (6) AU2013203445C1 (https=)
BR (1) BR112014019462B1 (https=)
CA (1) CA2862885C (https=)
CL (1) CL2014002077A1 (https=)
CO (1) CO7141407A2 (https=)
EA (1) EA038152B1 (https=)
EC (1) ECSP14014870A (https=)
HK (1) HK1202261A1 (https=)
IL (2) IL233833B (https=)
MX (2) MX393165B (https=)
NI (1) NI201400086A (https=)
NZ (1) NZ627980A (https=)
PE (1) PE20150092A1 (https=)
PH (1) PH12014501750A1 (https=)
SG (1) SG11201404705YA (https=)
TW (4) TW202231268A (https=)
WO (1) WO2013119677A1 (https=)
ZA (1) ZA201405511B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1663197T1 (sl) 2003-09-09 2008-06-30 Biogen Idec Internat Gmbh Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme
LT2801354T (lt) 2004-10-08 2017-06-26 Forward Pharma A/S Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį
SI2139467T1 (sl) * 2007-02-08 2017-01-31 Biogen Ma Inc. Zaščita živčevja pri demielinizacijskih obolenjih
HRP20140640T1 (hr) 2008-08-19 2014-11-21 Xenoport, Inc. Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe
SMT201800098T1 (it) 2011-06-08 2018-03-08 Biogen Ma Inc Processo per la preparazione di dimetilfumarato cristallino e con purezza elevata
NZ627980A (en) * 2012-02-07 2016-12-23 Biogen Ma Inc Pharmaceutical compositions containing dimethyl fumarate
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
AR094277A1 (es) 2012-12-21 2015-07-22 Biogen Idec Inc Derivados de fumarato sustituidos con deuterio
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
BR112015022854A2 (pt) 2013-03-14 2017-07-18 Alkermes Pharma Ireland Ltd pró-farmacos de fumaratos e uso do mesmo no tratamento de várias doenças
US20140275250A1 (en) * 2013-03-15 2014-09-18 Xenoport, Inc. Methods of Administering Monomethyl Fumarate
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
JP6581088B2 (ja) 2013-12-12 2019-09-25 アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． フマル酸ジメチルを含む医薬組成物
EP3079663A1 (en) 2013-12-13 2016-10-19 Biogen MA Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
AU2015222880B2 (en) 2014-02-28 2016-11-24 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10391160B2 (en) 2014-03-14 2019-08-27 Biogen Ma Inc. Dimethyl fumarate and vaccination regimens
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016057133A1 (en) * 2014-10-08 2016-04-14 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
AU2014414316B2 (en) * 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
MA40990A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle
CN104490849A (zh) * 2014-11-24 2015-04-08 广东东阳光药业有限公司 一种高密度的富马酸二甲酯肠溶颗粒及其制备方法
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
EP4056179A1 (en) 2014-12-11 2022-09-14 Actelion Pharmaceuticals Ltd Dosing regimen for ponesimod, a selective s1p1 receptor agonist
WO2016126540A1 (en) * 2015-02-02 2016-08-11 Enspire Group LLC Stabilized dialkyl fumarate compositions
HUE055210T2 (hu) * 2015-02-08 2021-11-29 Alkermes Pharma Ireland Ltd Monometilfumarát prodrug készítmények
WO2016147108A1 (en) * 2015-03-17 2016-09-22 Hetero Research Foundation Pharmaceutical compositions of dimethyl fumarate
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
CA2987895A1 (en) 2015-06-01 2016-12-08 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
MX387092B (es) 2015-06-17 2025-03-19 Biogen Ma Inc Particulas de dimetilfumarato y composiciones farmaceuticas de estas.
WO2017056107A1 (en) 2015-09-28 2017-04-06 Natco Pharma Ltd Pharmaceutical compositions of dimethyl fumarate
AU2016344673A1 (en) * 2015-10-28 2018-05-17 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
WO2017114593A1 (en) * 2015-12-31 2017-07-06 Zaklady Farmaceutyczne Polpharma S.A. Process for preparation of an enteric coated granulate comprising dimethyl fumarate
PL3407873T3 (pl) * 2016-01-28 2025-01-13 Zakłady Farmaceutyczne POLPHARMA S.A. Sposób otrzymywania granulatu zawierającego fumaran dimetylu
JP6902043B2 (ja) * 2016-02-11 2021-07-14 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． フマル酸ジメチルを含む医薬ビーズ製剤
WO2017145036A1 (en) * 2016-02-25 2017-08-31 Aurobindo Pharma Ltd Pharmaceutical compositions comprising dimethyl fumarate
TR201616998A1 (en) 2016-11-23 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi DELAYED RELEASE DOSING FORMS WITH DIMETHYL FUMARATE
CN110475547A (zh) * 2017-03-17 2019-11-19 维塔利斯公司 治疗多发性硬化症的组合物和方法
MA49448A (fr) 2017-06-23 2020-04-29 Almirall Sa Compositions pharmaceutiques contenant du fumarate de diméthyle
WO2020055739A1 (en) * 2018-09-10 2020-03-19 Vitalis Llc Fumaric acid compositions with increased bioavailability and reduced side effects
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
TR201818293A2 (tr) 2018-11-30 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül
WO2021092536A1 (en) 2019-11-08 2021-05-14 The Children's Hospital Of Philadelphia Compositions and methods for treating macrophage activation syndrome
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
US20230099229A1 (en) * 2020-03-13 2023-03-30 Reprise Pharmaceuticals, Inc. Methods of treating multiple sclerosis
EP4146190A2 (en) 2020-05-06 2023-03-15 Imcyse SA Combination treatment for fumarate-related diseases
AU2022285951A1 (en) * 2021-06-04 2024-01-04 Zim Laboratories Limited Delayed release compositions of dimethyl fumarate
AU2022422597A1 (en) 2021-12-23 2024-07-11 Gencaps Sàrl Drug delivery system comprising monomethyl fumarate
CN115590831A (zh) * 2022-10-26 2023-01-13 力品药业（厦门）股份有限公司（Cn） 一种富马酸二甲酯缓释微片及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153927A (en) 1966-08-25 1969-06-04 Wilhelm Hoerrmann Medicinal Composition Suitable For Treating Diseases Of The Retina
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5424332A (en) 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US5484610A (en) 1991-01-02 1996-01-16 Macromed, Inc. pH and temperature sensitive terpolymers for oral drug delivery
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
FI109088B (fi) * 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
DE19814358C2 (de) * 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) * 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US6537584B1 (en) 1999-11-12 2003-03-25 Macromed, Inc. Polymer blends that swell in an acidic environment and deswell in a basic environment
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
US7217431B2 (en) 2001-07-06 2007-05-15 Lifecycle Pharma A/S Controlled agglomeration
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
DE10214031A1 (de) 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
WO2004082615A2 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
SI1663197T1 (sl) * 2003-09-09 2008-06-30 Biogen Idec Internat Gmbh Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
LT2801354T (lt) * 2004-10-08 2017-06-26 Forward Pharma A/S Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį
EP1915334A2 (en) * 2005-07-07 2008-04-30 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
US20080299196A1 (en) 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US9125803B2 (en) * 2005-12-30 2015-09-08 Shionogi Inc. Gastric release pulse system for drug delivery
MX2009011493A (es) * 2007-04-25 2009-11-09 Teva Pharma Complejo de excipiente farmaceutico.
CN101917975B (zh) * 2007-12-21 2013-05-08 麦克内尔-Ppc股份有限公司 片剂的制造
BRPI0912842A8 (pt) * 2008-05-20 2019-01-29 Cerenis Therapeutics Holding composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
HRP20140640T1 (hr) * 2008-08-19 2014-11-21 Xenoport, Inc. Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe
JP2012514623A (ja) 2009-01-09 2012-06-28 フォーワード・ファルマ・アクティーゼルスカブ １またはそれ以上のフマル酸エステルを含む医薬組成物
WO2010079222A1 (en) * 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US20120165404A1 (en) * 2009-04-29 2012-06-28 Biogen Idec Ma Inc. Treatment of neurodegeneration and neuroinflammation
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
HUE025878T2 (en) 2010-02-12 2016-05-30 Biogen Ma Inc Neuroprotection in demyelinating diseases
NZ627980A (en) * 2012-02-07 2016-12-23 Biogen Ma Inc Pharmaceutical compositions containing dimethyl fumarate

Similar Documents

Publication Publication Date Title
JP2017222705A5 (https=)
JP2015506377A5 (https=)
KR101378973B1 (ko) 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
US10258622B2 (en) Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
US20080014271A1 (en) Novel pharmaceutical compositions comprising levetiracetam
US20150209291A1 (en) High drug load tablet
JP2020500176A (ja) 医薬製剤
CN102300558A (zh) 有机化合物的盖伦制剂
WO2009066315A2 (en) Sustained release compositions of trimetazidine and process for preparation thereof
JP2015501808A5 (https=)
KR101907116B1 (ko) 에스오메프라졸, 또는 약학적으로 허용 가능한 그의 염을 포함하는, pH-의존성 약물 방출 특성이 개선된 제형
KR101907881B1 (ko) 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
US20120231051A1 (en) Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
AU2016231883B2 (en) Pharmaceutical compositions of dimethyl fumarate
WO2010023690A2 (en) Prolonged release formulation of amisulpride
JP2019532960A (ja) エソメプラゾール含有複合カプセル剤及びその製造方法
KR20160076928A (ko) 푸마르산 에스테르를 함유하는 미니-정제 형태의 약제학적 제제
AU2013366640A1 (en) Tablet composition comprising cinacalcet hydrochloride
WO2021197451A1 (zh) 一种替格瑞洛的多元制剂
WO2017145036A1 (en) Pharmaceutical compositions comprising dimethyl fumarate
WO2009087690A2 (en) Multiparticulate extended release pharmaceutical composition of carbamazepine and process for manufacturing the same
JP2015503555A (ja) ボセンタン制御放出性経口製剤
GR1010345B (el) Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
WO2012050539A1 (en) Pharmaceutical composition comprising eplerenone
US20250170065A1 (en) Therapeutic compounds, formulations, and use thereof